To The Moon

Some billionaire hedge fund managers are scaling back their holdings of Nvidia, while ramping up their exposure to Bitcoin.According to some top investors, Bitcoin's price could hit $3.8 million by the year 2030.In addition to its upside potential, Bitcoin also provides unique risk diversification benefits, especially for institutional investors.And Wood is hardly alone in calling for a major rally in Bitcoin's price. Now that Bitcoin has become the centerpiece of the Trump administration's pro-crypto policy agenda, there's reason to think that Bitcoin could hit $1 million much sooner than anyone thought. There's even

We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off. In this article, we are going to take a look at where Amazon.com, Inc. stands against the other stocks.In a fresh appearance on CNBC's Squawk on the Street, Jim Cramer cautioned viewers to not be caught up by the energy that's gripped the US stock market since President Donald Trump resumed charge. "Things are happening very fast. And I want so much to slow it down," he stated. Cramer mentioned an article that mentioned "the burst of energy, some good, some bad," adding that not every remark made by the President is investment advice. He believes that "a lot of people want to do that. [treat all of Trump's remarks as investable]" They wanna do oil and gas, they wanna do with interest rates," he added and shared "They have to remember that he doesn't have the authority" particularly when it comes to determining interest rates.Another topic that Cramer touched on was SpaceX's Starlink s

KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platform. Interim readout from REWRITE expected in the second half of 2025. Korro to advance additional pipeline programs towards clinical development. “We have evolved from a research organization to a clinical-stage drug development organization with our first participant in the REWRITE study recently dosed with KRRO-110. We have taken time to build our pipeline to demonstrate the versatility of RNA editing, building on data from other oligonucleotide programs,” said Ram Aiyar, PhD, President and CEO. “Over the next three years, we expect to take three product candidates into the clinic, in two tissue types with a single modular platform. This will be the crux of our 3-2-1 strategy through 2027. I am excited about the prospect that RNA editing holds beyond the treatment of rare genetic disease and applying our platform to highly prevalent diseases.”

KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platform. Interim readout from REWRITE expected in the second half of 2025. Korro to advance additional pipeline programs towards clinical development. “We have evolved from a research organization to a clinical-stage drug development organization with our first participant in the REWRITE study recently dosed with KRRO-110. We have taken time to build our pipeline to demonstrate the versatility of RNA editing, building on data from other oligonucleotide programs,” said Ram Aiyar, PhD, President and CEO. “Over the next three years, we expect to take three product candidates into the clinic, in two tissue types with a single modular platform. This will be the crux of our 3-2-1 strategy through 2027. I am excited about the prospect that RNA editing holds beyond the treatment of rare genetic disease and applying our platform to highly prevalent diseases.”

Korro Bio (KRRO) has an average rating of buy and mean price target of $136.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an

Korro Bio (KRRO) has an average rating of buy and mean price target of $136.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an

Biopharma Korro Bio ($KRRO) has been making significant strides in genetic medicine, including developing RNA editing to address rare and widesprea...

Trump Picks Truth Social CEO Devin Nunes as Chairman of President's Intelligence Advisory Board